Cases & Investigations
Harmony Biosciences Holdings, Inc.
Type: Investigations
Defendant(s): Harmony Biosciences Holdings, Inc.
Stock Symbol: NASDAQ: HRMY
Harmony is a commercial and clinical stage drug company that focuses on therapies for patients with rare neurological diseases.
Before the market opened on March 28, 2023, Scorpion Capital published a short seller report headlined “The Latest Price-Gouging Ploy By The Grifter Who Inspired Convicted Felon Martin Shkreli, But This Time People Have Blood On Their Hands: A $175,000 Per Year Drug With Alarming Toxicity And A Trail Of Covered-Up Deaths And Injuries; No Efficacy; A Non-Existent Mechanism of Action; Sham Patents; Based On Scam Clinical Trials In Places Like Russia And Turkey By A French Quack; Pushed Via False Advertising And A Vast Off-Label And Physician Kickback Scheme.” The Report alleges the FDA has received dozens of serious adverse event reports regarding Harmony’s FDA approved drug WAKIX that “paint a devastating picture of the drug’s risk.” Furthermore, Scorpion Capital wrote that, based on information in the Report, it “believe[s] explosive information was concealed from the FDA that would have prevented approval in 2019.” On this news, Harmony’s stock price fell $10.70 per share to $30.80 on March 28, 2023, down 25.8% on very heavy volume.
Contact Instructions